BACKGROUND: The optimal use of new therapies in metastatic castration-resistant prostate cancer (mCRPC) remains to be clarified. Prostate-specific antigen (PSA) response used as a pharmacodynamic end-point may help identify patients with early resistance to new androgen receptor-pathway inhibitors. We aimed to determine the clinical significance of early PSA response (EPR) during therapy with enzalutamide, abiraterone acetate (AA) and orteronel in mCRPC. METHODS: Data from patients recruited in clinical trials were studied. PSA values were obtained at baseline and 28 d after treatment initiation. EPR defined as a decline >50% from baseline was calculated according to the Prostate Cancer Working Group 2 criteria. The effects of clinical characteristics on radiographic progression-free survival (rPFS) and overall survival (OS) were examined using the Cox model. RESULTS: EPR was assessed in 118 patients treated in clinical trials and was found to be associated with longer rPFS and OS (P < 0.0001 for both). Median rPFS was 13.9 and 5.6 months (hazard ratio [HR]:0.38, P < 0.001) for patients with and without an EPR, respectively. Median OS was 32.2 months in patients with an EPR and 15.9 months in patients without an EPR (HR: 0.4, P < 0.01). EPR remained prognostic for OS in multivariate analyses (HR: 0.5, p=0.009) that included validated pre-therapeutic prognostic factors for mCRPC. Prognostic values of EPR for rPFS and OS were confirmed in an independent cohort of 95 AA-treated non-trial patients. CONCLUSIONS: EPR is an independent prognostic factor in patients with mCRPC treated with next-generation androgen pathway inhibitors and may be useful for the therapeutic management of these patients.
BACKGROUND: The optimal use of new therapies in metastatic castration-resistant prostate cancer (mCRPC) remains to be clarified. Prostate-specific antigen (PSA) response used as a pharmacodynamic end-point may help identify patients with early resistance to new androgen receptor-pathway inhibitors. We aimed to determine the clinical significance of early PSA response (EPR) during therapy with enzalutamide, abiraterone acetate (AA) and orteronel in mCRPC. METHODS: Data from patients recruited in clinical trials were studied. PSA values were obtained at baseline and 28 d after treatment initiation. EPR defined as a decline >50% from baseline was calculated according to the Prostate Cancer Working Group 2 criteria. The effects of clinical characteristics on radiographic progression-free survival (rPFS) and overall survival (OS) were examined using the Cox model. RESULTS: EPR was assessed in 118 patients treated in clinical trials and was found to be associated with longer rPFS and OS (P < 0.0001 for both). Median rPFS was 13.9 and 5.6 months (hazard ratio [HR]:0.38, P < 0.001) for patients with and without an EPR, respectively. Median OS was 32.2 months in patients with an EPR and 15.9 months in patients without an EPR (HR: 0.4, P < 0.01). EPR remained prognostic for OS in multivariate analyses (HR: 0.5, p=0.009) that included validated pre-therapeutic prognostic factors for mCRPC. Prognostic values of EPR for rPFS and OS were confirmed in an independent cohort of 95 AA-treated non-trial patients. CONCLUSIONS: EPR is an independent prognostic factor in patients with mCRPC treated with next-generation androgen pathway inhibitors and may be useful for the therapeutic management of these patients.
Authors: Sofia España; Maria Ochoa de Olza; Nuria Sala; Josep Maria Piulats; Ulises Ferrandiz; Olatz Etxaniz; Lucia Heras; Oscar Buisan; Juan Carlos Pardo; Jose F Suarez; Pilar Barretina; Josep Comet; Xavier Garcia Del Muro; Lauro Sumoy; Albert Font Journal: Cancer Manag Res Date: 2020-10-16 Impact factor: 3.989
Authors: Andrew J Armstrong; Fred Saad; Carl Dmuchowski; Neal D Shore; Karim Fizazi; Mohammad Hirmand; David Forer; Howard I Scher; Johann De Bono Journal: Cancer Date: 2017-02-07 Impact factor: 6.860
Authors: Cecília M Alvim; André Mansinho; Rita S Paiva; Raquel Brás; Patrícia M Semedo; Soraia Lobo-Martins; Carolina B da Ponte; Daniela Macedo; Leonor Ribeiro; José P Dos Reis; Isabel Fernandes; Luís Costa Journal: Future Sci OA Date: 2019-12-12
Authors: Rebeca Lozano; David Lorente; Isabel M Aragon; Nuria Romero-Laorden; Paz Nombela; Joaquim Mateo; Alison H M Reid; Ylenia Cendón; Diletta Bianchini; Casilda Llacer; Shahneen K Sandhu; Adam Sharp; Pasquale Rescigno; Teresa Garcés; Maria I Pacheco; Penelope Flohr; Christophe Massard; Pedro P López-Casas; Elena Castro; Johann S de Bono; David Olmos Journal: Cancers (Basel) Date: 2021-05-12 Impact factor: 6.639
Authors: Simon Linder; Henk G van der Poel; Andries M Bergman; Wilbert Zwart; Stefan Prekovic Journal: Endocr Relat Cancer Date: 2018-10-31 Impact factor: 5.678
Authors: Antonio Finelli; Tomasz M Beer; Simon Chowdhury; Christopher P Evans; Karim Fizazi; Celestia S Higano; Janet Kim; Lisa Martin; Fred Saad; Olli Saarela Journal: JAMA Netw Open Date: 2021-06-01